Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
- 31 October 1995
- Vol. 46 (4) , 477-483
- https://doi.org/10.1016/s0090-4295(99)80258-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Safety assessment of terazosin in thetreatment of patients with symptomatic benign prostatic hyperplasia: A combined analysisUrology, 1994
- The costs of prostatectomy for benign prostatic hyperplasiaThe Prostate, 1993
- Cost-Effectiveness AnalysisPharmacoEconomics, 1993
- The American Urological Association Symptom Index for Benign Prostatic HyperplasiaJournal of Urology, 1992
- Mortality and reoperation followingprostatectomy: Outcomes in a medicare populationUrology, 1991
- Avoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical CompaniesNew England Journal of Medicine, 1991
- The clinical development of a 5α-reductase inhibitor, finasterideThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- An Assessment of Prostatectomy for Benign Urinary Tract ObstructionJAMA, 1988
- Decision AnalysisNew England Journal of Medicine, 1987
- Natural history of benign prostatic hypertrophy and acute urinary retentionUrology, 1976